- Home
- GGR vs CNTX Comparison
GGR vs CNTX Comparison
Compare GGR & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGR
- CNTX
- Stock Information
- Founded
- GGR 2011
- CNTX 2015
- Country
- GGR Taiwan
- CNTX United States
- Employees
- GGR N/A
- CNTX N/A
- Industry
- GGR Auto Manufacturing
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- GGR Consumer Discretionary
- CNTX Health Care
- Exchange
- GGR Nasdaq
- CNTX Nasdaq
- Market Cap
- GGR 80.6M
- CNTX 78.0M
- IPO Year
- GGR N/A
- CNTX 2021
- Fundamental
- Price
- GGR $0.35
- CNTX $0.89
- Analyst Decision
- GGR Hold
- CNTX Strong Buy
- Analyst Count
- GGR 2
- CNTX 5
- Target Price
- GGR $0.50
- CNTX $5.50
- AVG Volume (30 Days)
- GGR 615.0K
- CNTX 183.2K
- Earning Date
- GGR 08-14-2025
- CNTX 08-06-2025
- Dividend Yield
- GGR N/A
- CNTX N/A
- EPS Growth
- GGR N/A
- CNTX N/A
- EPS
- GGR N/A
- CNTX N/A
- Revenue
- GGR $304,551,000.00
- CNTX N/A
- Revenue This Year
- GGR N/A
- CNTX N/A
- Revenue Next Year
- GGR $5.00
- CNTX N/A
- P/E Ratio
- GGR N/A
- CNTX N/A
- Revenue Growth
- GGR N/A
- CNTX N/A
- 52 Week Low
- GGR $0.19
- CNTX $0.49
- 52 Week High
- GGR $1.65
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- GGR 58.76
- CNTX 74.42
- Support Level
- GGR $0.31
- CNTX $0.62
- Resistance Level
- GGR $0.35
- CNTX $0.67
- Average True Range (ATR)
- GGR 0.03
- CNTX 0.07
- MACD
- GGR 0.00
- CNTX 0.03
- Stochastic Oscillator
- GGR 54.90
- CNTX 71.13
About GGR Gogoro Inc.
Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.